VPL vs XBI
Vanguard FTSE Pacific ETF vs SPDR S&P Biotech ETF
- • VPL has the lower expense ratio at 0.07% vs 0.35% for XBI.
- • VPL pays a higher dividend yield (2.23%).
Side-by-side metrics
| Metric | VPL | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.07% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.23% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $12.66B | $10.92B |
YTD return | 17.89% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.17 | 1.01 |
P/E ratio | 13.13 | — |
Last price | $108.00 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VPL top holdings
| 005930.KQ | Samsung Electronics Co Ltd | 7.10% |
| 000660.KQ | SK hynix Inc | 5.82% |
| 8306.T | Mitsubishi UFJ Financial Group Inc | 1.98% |
| BHP.AX | BHP Group Ltd | 1.69% |
| 7203.T | Toyota Motor Corp | 1.51% |
| CBA.AX | Commonwealth Bank of Australia | 1.37% |
| 8035.T | Tokyo Electron Ltd | 1.30% |
| 6857.T | Advantest Corp | 1.25% |
| 8316.T | Sumitomo Mitsui Financial Group Inc | 1.25% |
| 6501.T | Hitachi Ltd | 1.20% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About VPL
VPL (Vanguard FTSE Pacific ETF) is Developed Pacific-region equities. Managed by Vanguard, the fund carries $12.7B in assets under management, an expense ratio of 0.07%, a dividend yield of 2.23%. Its largest holding is Samsung Electronics Co Ltd (005930.KQ), which represents 7.1% of the portfolio. Real Estate is the fund's largest sector exposure at 3.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.